GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Return-on-Tangible-Equity

Psyence Biomedical (Psyence Biomedical) Return-on-Tangible-Equity : -418.80% (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Psyence Biomedical's annualized net income for the quarter that ended in Mar. 2023 was $-3.10 Mil. Psyence Biomedical's average shareholder tangible equity for the quarter that ended in Mar. 2023 was $0.74 Mil. Therefore, Psyence Biomedical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2023 was -418.80%.

The historical rank and industry rank for Psyence Biomedical's Return-on-Tangible-Equity or its related term are showing as below:

PBM' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -418.8   Med: -237.61   Max: -56.42
Current: -418.8

During the past 3 years, Psyence Biomedical's highest Return-on-Tangible-Equity was -56.42%. The lowest was -418.80%. And the median was -237.61%.

PBM's Return-on-Tangible-Equity is ranked worse than
93.12% of 1308 companies
in the Biotechnology industry
Industry Median: -48.465 vs PBM: -418.80

Psyence Biomedical Return-on-Tangible-Equity Historical Data

The historical data trend for Psyence Biomedical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Return-on-Tangible-Equity Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Return-on-Tangible-Equity
- -56.42 -418.80

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Return-on-Tangible-Equity - -56.42 -418.80

Competitive Comparison of Psyence Biomedical's Return-on-Tangible-Equity

For the Biotechnology subindustry, Psyence Biomedical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Return-on-Tangible-Equity falls into.



Psyence Biomedical Return-on-Tangible-Equity Calculation

Psyence Biomedical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-3.097/( (1.677+-0.198 )/ 2 )
=-3.097/0.7395
=-418.80 %

Psyence Biomedical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2023 )  (Q: Mar. 2022 )(Q: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2023 )  (Q: Mar. 2022 )(Q: Mar. 2023 )
=-3.097/( (1.677+-0.198)/ 2 )
=-3.097/0.7395
=-418.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (Mar. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Psyence Biomedical  (NAS:PBM) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Psyence Biomedical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines